Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model

Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model

Immune-checkpoint-inhibitors (ICI) target key regulators of the immune system expressed by cancer cells that mask those from recognition by the immune system. They have improved the outcome for patients with various cancer types, such as melanoma. ICI-based therapy is frequently accompanied by immun...

Full description

Saved in:
Bibliographic Details
Main Authors: Caroline Schoenherr, Stefan Pietzsch, Cristina Barca, Franziska E. Müller, Frauke S. Bahr, Martina Kasten, Andre Zeug, Sergej Erschow, Christine S. Falk, Evgeni Ponimaskin, James T. Thackeray, Denise Hilfiker-Kleiner, Melanie Ricke-Hoch
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Molecular Medicine
Subjects:
immune checkpoint inhibitors
PD-L1
inflammation
cancer
cardio-oncology
cardiotoxicity
Online Access:https://www.frontiersin.org/articles/10.3389/fmmed.2024.1487526/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fmmed.2024.1487526/full

Similar Items